News stories about Oramed Pharmaceuticals (NASDAQ:ORMP) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Oramed Pharmaceuticals earned a coverage optimism score of 0.16 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 45.0093755844495 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Several analysts have issued reports on the company. ValuEngine downgraded Oramed Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, December 5th. HC Wainwright restated a “buy” rating and issued a $25.00 price objective on shares of Oramed Pharmaceuticals in a report on Thursday, October 5th. Finally, B. Riley restated a “buy” rating and set a $20.00 price objective on shares of Oramed Pharmaceuticals in a report on Monday, December 11th.
Shares of Oramed Pharmaceuticals (NASDAQ ORMP) traded up $0.09 on Thursday, reaching $8.81. 23,900 shares of the company’s stock traded hands, compared to its average volume of 46,232. The firm has a market capitalization of $126.04, a P/E ratio of -11.15 and a beta of 1.09. Oramed Pharmaceuticals has a 1-year low of $5.85 and a 1-year high of $11.34.
ILLEGAL ACTIVITY WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Price” was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://stocknewstimes.com/2018/01/11/oramed-pharmaceuticals-ormp-given-daily-news-impact-score-of-0-16.html.
Oramed Pharmaceuticals Inc (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection.
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.